Separate securities class action notices cite Insulet Omnipod device-correction disclosures and Intuit TurboTax growth and competition allegations, with lead plaintiff deadlines of August 31 and September 8, 2026.
Two separate law-firm announcements describe unrelated securities class actions. In the Insulet case, Bleichmar Fonti & Auld LLP said a complaint filed in the U.S. District Court for the District of Massachusetts, Hu v. Insulet Corporation et al., No. 26-cv-13062, alleges Insulet and certain senior executives violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by misrepresenting the safety of Omnipod products and the company’s ability to produce “medical grade quality at consumer electronic scale” before voluntary Medical Device Corrections in March and May 2026. Investors have until August 31, 2026 to seek appointment as lead plaintiff. Separately, Robbins Geller Rudman & Dowd LLP said Intuit investors who bought securities between August 22, 2025 and May 20, 2026 have until September 8, 2026 to seek lead plaintiff status in Baldwin v. Intuit Inc., No. 26-cv-07086 (N.D. Cal.), which alleges Intuit misled investors about TurboTax growth, competitive pressures, and the reliability of 2026 guidance.